Corporate Overview
BioKey Cayman acquired 100% equity in BioKey, Inc. from ABVC BioPharma in May 2025 as part of a corporate reorganization. This strategic move strengthens our life sciences platform, enabling us to support innovation and long-term growth through our established pharmaceutical development and manufacturing capabilities.
Business Segments
Pharmaceutical Development
Comprehensive drug development services including formulation, analytical methods, stability testing, and regulatory support for global pharmaceutical innovation.
CRO/CDMO Services
Integrated contract research and manufacturing solutions, providing pilot scale production, clinical supply, and quality assurance for life sciences partners.
Nutraceuticals & Botanicals
Specialized expertise in functional supplements and botanical formulations, leveraging advanced analytical methods to ensure purity and efficacy.